Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease.
Adenine
Angiotensin-Converting Enzyme 2
/ genetics
Animals
Aristolochic Acids
COVID-19
/ metabolism
Disease Models, Animal
Down-Regulation
Humans
Imidazoles
/ administration & dosage
Kidney
/ metabolism
Mice
Mice, Inbred C57BL
Organ Specificity
Renal Insufficiency, Chronic
/ metabolism
SARS-CoV-2
/ physiology
Tetrazoles
/ administration & dosage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 08 2021
19 08 2021
Historique:
received:
18
03
2021
accepted:
04
08
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Elevated angiotensin-converting enzyme 2 (ACE2) expression in organs that are potential targets of severe acute respiratory syndrome coronavirus 2 may increase the risk of coronavirus disease 2019 (COVID-19) infection. Previous reports show that ACE2 alter its tissue-specific expression patterns under various pathological conditions, including renal diseases. Here, we examined changes in pulmonary ACE2 expression in two mouse chronic kidney disease (CKD) models: adenine-induced (adenine mice) and aristolochic acid-induced (AA mice). We also investigated changes in pulmonary ACE2 expression due to renin-angiotensin system (RAS) blocker (olmesartan) treatment in these mice. Adenine mice showed significant renal functional decline and elevated blood pressure, compared with controls. AA mice also showed significant renal functional decline, compared with vehicles; blood pressure did not differ between groups. Renal ACE2 expression was significantly reduced in adenine mice and AA mice; pulmonary expression was unaffected. Olmesartan attenuated urinary albumin excretion in adenine mice, but did not affect renal or pulmonary ACE2 expression levels. The results suggest that the risk of COVID-19 infection may not be elevated in patients with CKD because of their stable pulmonary ACE2 expression. Moreover, RAS blockers can be used safely in treatment of COVID-19 patients with CKD.
Identifiants
pubmed: 34413390
doi: 10.1038/s41598-021-96294-8
pii: 10.1038/s41598-021-96294-8
pmc: PMC8377123
doi:
Substances chimiques
Aristolochic Acids
0
Imidazoles
0
Tetrazoles
0
olmesartan
8W1IQP3U10
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16843Informations de copyright
© 2021. The Author(s).
Références
Sci Rep. 2018 Feb 12;8(1):2846
pubmed: 29434287
Hypertension. 2010 May;55(5):1157-64
pubmed: 20231526
J Pathol. 2011 Dec;225(4):618-27
pubmed: 22009550
PLoS One. 2018 Jun 13;13(6):e0198144
pubmed: 29897923
J Mol Cell Cardiol. 2014 Jan;66:167-76
pubmed: 24332999
J Am Heart Assoc. 2017 Mar 6;6(3):
pubmed: 28264860
Nephron. 2019;141(1):61-74
pubmed: 30326474
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Ann Med. 2020 Nov;52(7):345-353
pubmed: 32643418
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Shock. 2015 Apr;43(4):395-404
pubmed: 25768373
J Am Soc Nephrol. 2020 Sep;31(9):1941-1943
pubmed: 32669323
Am J Physiol Renal Physiol. 2010 Jun;298(6):F1523-32
pubmed: 20357030
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Am J Pathol. 2009 Apr;174(4):1203-11
pubmed: 19264908
Clin Sci (Lond). 2021 Feb 12;135(3):465-481
pubmed: 33479758
Travel Med Infect Dis. 2020 Sep - Oct;37:101825
pubmed: 32763496
Respirology. 2021 May;26(5):442-451
pubmed: 33455043
J Am Soc Nephrol. 2006 Nov;17(11):3067-75
pubmed: 17021266
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Clin Sci (Lond). 2014 Aug;127(4):243-9
pubmed: 24564768
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1017-1025
pubmed: 32634716
J Med Virol. 2021 Apr;93(4):2084-2089
pubmed: 33038021
Curr Hypertens Rep. 2020 Feb 29;22(3):22
pubmed: 32114685
J Virol. 2005 Dec;79(23):14614-21
pubmed: 16282461
Kidney Int. 2020 Apr;97(4):728-740
pubmed: 31948598
Epigenomics. 2021 Mar;13(6):423-436
pubmed: 33678000
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Mol Ther Methods Clin Dev. 2020 May 22;18:1-6
pubmed: 32537478
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Atherosclerosis. 2020 Dec;314:58-62
pubmed: 33161318
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Curr Opin Nephrol Hypertens. 2007 Mar;16(2):116-21
pubmed: 17293686
Hypertension. 2010 Feb;55(2):207-13
pubmed: 20038757
Kidney Int. 2004 Nov;66(5):1815-25
pubmed: 15496152
Hypertension. 2008 Oct;52(4):672-8
pubmed: 18725581
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
Nephron Clin Pract. 2011;117(1):c57-66
pubmed: 20689326
Am J Physiol Renal Physiol. 2009 Feb;296(2):F398-405
pubmed: 19004932
Sci Rep. 2019 Apr 17;9(1):6201
pubmed: 30996242
Kidney Int. 2008 Mar;73(5):595-607
pubmed: 18094681
Hypertens Res. 2014 Jul;37(7):616-20
pubmed: 24599018
Life Sci. 2016 Sep 15;161:27-36
pubmed: 27493078
Clin Sci (Lond). 2010 Feb;118(4):269-79
pubmed: 19698082